Background Disappointing outcomes in Sjögren’s disease (SjD) trials underscore the need for reliable, sensitive endpoints.
Background Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of ...
Objectives Patients with primary Sjögren’s disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was ...
Background Data on cardiorespiratory fitness (CRF) in psoriatic arthritis (PsA) are scarce. This study aimed to determine the ...
Objectives A few studies on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treatments have shown the therapeutic efficacy of mycophenolate mofetil (MMF). However, the ...
Objective A new adult-onset autoinflammatory syndrome has been described, named VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic). We aimed to compare the clinical characteristics, the ...
Objective A comparison of cryoneurolysis or radio frequency (RF) with placebo in patients with facetogenic chronic low back pain (LBP) for patient global impression of change (PGIC), pain intensity, ...
Objectives Bisphenol A (BPA), a xenoestrogen that can alter DNA methylation status, has been implicated in the pathogenesis of systemic lupus erythematosus (SLE). This study aimed to investigate ...
Objective Glucocorticoids (GC) are a cornerstone in treating antineutrophil cytoplasmic antibodies-associated vasculitides (AAV), however, they add to morbidity and mortality. To date, GC toxicity in ...
We have evaluated the clinical value of the ELISA for anti-AT 1 R AAbs and anti-ET A R AAbs in two large, clinically well-defined cohorts of SSc patients from the Netherlands. Anti-AT 1 R AAbs and ...
Objectives Patients with connective tissue diseases can develop interstitial lung disease (ILD), leading to a progressive fibrosing ILD (PF-ILD) phenotype in some cases. We aimed to investigate the ...
Objectives To characterise the comparative effectiveness of combination therapy (a tumour necrosis factor inhibitor (TNFi) and a conventional synthetic disease-modifying antirheumatic drug (csDMARD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results